Actively Recruiting
A Real-world Data and Sample Compendium of Frail and/or Multiply Treated Large B-cell Lymphoma
Led by The Clatterbridge Cancer Centre NHS Foundation Trust · Updated on 2026-01-12
800
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
LBCL is a cancer of the lymphatic system where B-cells (a type of white blood cell) experience uncontrolled growth. The standard treatment for LBCL is a combination of chemotherapy and immunotherapy, referred to as chemo-immunotherapy. Currently, the best results in the treatment of LBCL is with a chemo-immunotherapy combination called R-CHOP or Pola-R-CHP. Full doses of treatment are not suitable for elderly or frail patients due to potential to cause side effects and heart problems. Such patients either receive a reduced dose called mini-R-CHOP or receive alternatives (e.g. R-GCVP or R-CEOP). Additionally, some patients treated with R-CHOP or Pola-R-CHP may not respond or may respond initially before relapsing. For these patients, treatment is not standardised, and practice varies between hospitals. ALMANAC aims to collect data about the management and outcomes of patients with LBCL who are unsuitable for standard treatments because they are not well enough to tolerate the side effects or because they have not responded or relapsed following initial treatment. In doing so, it will guide research into LBCL leading to a better understanding of this condition and better outcomes.
CONDITIONS
Official Title
A Real-world Data and Sample Compendium of Frail and/or Multiply Treated Large B-cell Lymphoma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Males and female subjects 16 years of age or older at the time of enrolment
- Ability to understand and sign written informed consent
- Previously untreated histologically proven Large B-cell non-Hodgkin's lymphoma (LBCL) as per WHO 2016 classification including all variants
- Cohort A: LBCL patients unfit for full dose R-CHOP/Pola-R-CHP including various specified subtypes and de novo transformed indolent B-cell lymphomas
- Cohort B: LBCL patients with relapsed/refractory disease after frontline chemo-immunotherapy including CAR-T therapy, and those previously in Cohort A with subsequent relapse
- Patients on other trials/studies are eligible
- Data for patients starting treatment less than 6 months before enrolment can be entered retrospectively
You will not qualify if you...
- Patients treated more than 6 months prior to trial enrolment (Cohort B)
- Patients eligible for full dose R-CHOP/Pola-R-CHP (Cohort A)
- Patients with central nervous system (CNS) lymphoma
- Lymphoid proliferations and lymphomas associated with immune suppression and dysregulation (e.g., Post-Transplant Lymphoproliferative Disorders)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
The Clatterbridge Cancer Centre NHS Foundation Trust
Liverpool, Merseyside, United Kingdom, L78YA
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here